tiprankstipranks
Trending News
More News >
Achieve Life Sciences (ACHV)
:ACHV
Advertisement

Achieve Life Sciences (ACHV) AI Stock Analysis

Compare
1,630 Followers

Top Page

ACHV

Achieve Life Sciences

(NASDAQ:ACHV)

Rating:37Underperform
Price Target:
Achieve Life Sciences is navigating typical early-stage biotech challenges, including zero revenue and significant financial losses. While there are promising developments such as the upcoming NDA submission and strong clinical trial progress, these are offset by high operating expenses and dependency on future financing and regulatory approvals. Technical indicators reflect a downward trend, and the valuation remains unattractive with a negative P/E ratio.
Positive Factors
Market Potential
Cytisinicline has the potential to become the first FDA-approved nicotine addiction drug in almost 20 years, highlighting its unique market position.
Regulatory Approval
The FDA has accepted its NDA for its smoking cessation treatment, cytisinicline, with a PDUFA date set for 6/20/26.
Strategic Partnerships
A strategic partnership with Omnicom to co-develop and execute a fully integrated, AI-enabled US launch strategy for cytisinicline has been announced, pending FDA approval.
Negative Factors
Operational Costs
An increase in 2025 and 2026 expense estimates, suggesting higher operational costs for the company in the coming years.

Achieve Life Sciences (ACHV) vs. SPDR S&P 500 ETF (SPY)

Achieve Life Sciences Business Overview & Revenue Model

Company DescriptionAchieve Life Sciences, Inc. (ACHV) is a clinical-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction. Operating primarily within the biopharmaceutical sector, the company's core focus is on addressing the global smoking health crisis by providing an alternative to existing smoking cessation therapies.
How the Company Makes MoneyAchieve Life Sciences generates revenue primarily through the development and potential future commercialization of its lead product, cytisinicline, which is currently in clinical trials. The company aims to earn income from the successful approval and sale of cytisinicline, targeting partnerships, licensing agreements, and collaborations with larger pharmaceutical companies to aid in distribution and marketing. Additionally, Achieve seeks funding through public and private investments to support its research and development activities. As it is still in the clinical stage, the company's current revenues are limited, and its financial strategy relies on securing further investment and eventual drug approval for market entry.

Achieve Life Sciences Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant advancements in regulatory submissions, strategic partnerships, and capital acquisition, indicating strong progress toward commercialization. However, the extended timeline to launch and potential pricing challenges present notable hurdles.
Q2-2025 Updates
Positive Updates
Successful NDA Submission for Cytisinicline
Achieve Life Sciences submitted a new drug application (NDA) for cytisinicline as a treatment for nicotine dependence to the FDA, marking a major regulatory milestone.
Strategic Partnership with Omnicom
Achieve formed a strategic commercial partnership with Omnicom to enhance its commercial launch strategy, leveraging Omnicom's expertise in health care marketing and advertising.
Significant Capital Raise
Achieve Life Sciences raised $49.3 million, strengthening its balance sheet and positioning the company to reach critical value inflection points in 2026, including potential product approval.
Positive Patient Survey Results
Patient surveys from the ORCA-OL study showed 98% believed cytisinicline contributed to reducing nicotine dependence, and 99% would recommend it to others.
Regulatory and Safety Milestones Achieved
FDA requested safety data milestones were met, with over 290 participants completing 1 year of cytisinicline treatment, ensuring robust safety data for the NDA.
Negative Updates
Extended Timeline to Product Launch
Product launch is anticipated in late 2026, which may impact revenue generation timelines and requires sustained investment over the next few years.
Potential Pricing Challenges
There may be challenges in positioning cytisinicline at a premium price relative to generic alternatives, which could impact market adoption and insurance coverage.
Company Guidance
During the Achieve Life Sciences second quarter 2025 earnings call, the company provided guidance on several key metrics and milestones. Achieve successfully submitted a new drug application (NDA) for cytisinicline as a treatment for nicotine dependence to the FDA, marking a significant regulatory milestone. They anticipate receiving the 74-day letter from the FDA in September, which will confirm the acceptance of their NDA for review. Achieve also announced a strategic partnership with Omnicom to support their commercial launch strategy, leveraging Omnicom's experience with over 100 product launches in the past three years. Financially, the company raised $49 million, strengthening their balance sheet with cash and equivalents totaling $55.4 million as of June 30, 2025. This funding is expected to support operations into the second half of 2026. Achieve's leadership shared their commitment to advancing regulatory, commercial, and financial objectives, aiming for a potential product launch in late 2026. The call emphasized the significant market opportunity, with 29 million Americans smoking and over 15 million annually attempting to quit, highlighting the unmet need for effective smoking cessation tools.

Achieve Life Sciences Financial Statement Overview

Summary
Achieve Life Sciences faces challenges typical of early-stage biotech firms, with no revenue, significant losses, and negative cash flows. Improvements in equity and financing inflows offer some stability, but the company remains in a precarious financial position until it can generate consistent revenue streams.
Income Statement
15
Very Negative
Achieve Life Sciences has consistently reported zero revenue, indicating a lack of commercialized products or services. The company has also experienced significant net losses over the years, including a net loss of $39.83 million in 2024. This trend highlights the financial challenges typical in the biotechnology industry during the R&D phase.
Balance Sheet
30
Negative
The company's debt-to-equity ratio improved significantly in 2024 due to increased stockholders' equity from negative to $20.9 million. However, the company still carries a notable amount of debt relative to its equity. The equity ratio of 54.1% in 2024 suggests a moderate reliance on equity financing, yet the previous negative equity poses potential risks.
Cash Flow
20
Very Negative
Achieve Life Sciences shows negative operating and free cash flows, consistent with its developmental stage. The operating cash flow to net income ratio indicates cash outflows are aligned with reported losses. While financing activities have provided substantial cash inflows, the negative free cash flow growth highlights ongoing cash burn.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue228.00K0.000.000.000.000.00
Gross Profit-3.00K-229.00K-228.00K-236.00K-250.00K-255.00K
EBITDA-49.25M-37.42M-26.73M-40.33M-32.90M-14.47M
Net Income-50.42M-39.83M-29.82M-41.88M-32.90M-14.66M
Balance Sheet
Total Assets58.94M38.63M19.37M29.97M47.52M40.30M
Cash, Cash Equivalents and Short-Term Investments55.40M34.36M15.55M24.77M43.02M35.85M
Total Debt9.96M9.96M16.73M16.20M73.00K169.00K
Total Liabilities17.27M17.73M20.82M21.67M19.47M3.01M
Stockholders Equity41.67M20.90M-1.45M8.30M28.04M37.29M
Cash Flow
Free Cash Flow-39.72M-29.77M-24.50M-37.55M-29.46M-13.49M
Operating Cash Flow-39.72M-29.77M-24.48M-37.55M-29.44M-13.47M
Investing Cash Flow43.04M-21.58M-21.00K0.00-17.00K-17.00K
Financing Cash Flow33.79M48.53M15.28M19.30M36.61M32.68M

Achieve Life Sciences Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.83
Price Trends
50DMA
2.64
Positive
100DMA
2.80
Positive
200DMA
3.08
Negative
Market Momentum
MACD
0.07
Positive
RSI
50.85
Neutral
STOCH
18.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACHV, the sentiment is Neutral. The current price of 2.83 is above the 20-day moving average (MA) of 2.78, above the 50-day MA of 2.64, and below the 200-day MA of 3.08, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 50.85 is Neutral, neither overbought nor oversold. The STOCH value of 18.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ACHV.

Achieve Life Sciences Risk Analysis

Achieve Life Sciences disclosed 65 risk factors in its most recent earnings report. Achieve Life Sciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Achieve Life Sciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
$192.96M-48.36%333.74%
51
Neutral
$7.95B-0.40-42.50%2.21%22.29%-1.85%
48
Neutral
$120.99M10.83-94.59%-67.67%-390.60%
43
Neutral
$128.47M-212.51%-9.69%
39
Underperform
$160.52M-26.94%26.33%
39
Underperform
$152.99M-780.29%20.13%
37
Underperform
$144.63M-120.11%-32.50%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ACHV
Achieve Life Sciences
2.83
-1.46
-34.03%
CLLS
Cellectis SA
2.68
0.42
18.58%
SPRO
Spero Therapeutics
2.15
0.78
56.93%
MIST
Milestone Pharmaceuticals
1.80
0.36
25.00%
NKTX
Nkarta
2.26
-3.65
-61.76%
IOBT
IO Biotech
1.95
1.05
116.67%

Achieve Life Sciences Corporate Events

Executive/Board Changes
Achieve Life Sciences Announces Board of Directors Changes
Neutral
Jan 10, 2025

Achieve Life Sciences announced changes in its board of directors with the resignation of Dr. Vaughn Himes and the appointment of Nancy R. Phelan and Kristen B. Slaoui. The new directors will receive compensation in line with the company’s non-employee director compensation program and are granted stock options with vesting conditions tied to their continued service.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025